Q1 2018 13F Holders as of 31 Mar 2018
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
6,235,531
-
Total 13F shares
-
4,695,186
-
Share change
-
+4,695,186
-
Total reported value
-
$47,920,000
-
Price per share
-
$10.24
-
Number of holders
-
22
-
Value change
-
+$47,920,000
-
Number of buys
-
22
Institutional Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) as of Q1 2018
As of 31 Mar 2018,
BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) was held by
22 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
4,695,186 shares.
The largest 10 holders included
FMR LLC, Artemis Investment Management LLP, BARCLAYS PLC, CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM, VANGUARD GROUP INC, ASCEND CAPITAL, LLC, Monashee Investment Management LLC, Marshall Wace North America L.P., Point72 Asset Management, L.P., and Dean Capital Investments Management, LLC.
This page lists
22
institutional shareholders reporting positions in this security
for the Q1 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.